Alexion Pharmaceuticals, Inc. (ALXN) Tops Q2 EPS by 10c; Boosts FY12 Outlook
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Join SI Premium – FREE
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q2 EPS of $0.47, $0.10 better than the analyst estimate of $0.37. Revenue for the quarter came in at $274.7 million versus the consensus estimate of $262.72 million.
Alexion Pharmaceuticals, Inc. sees FY2012 EPS of $1.78-$1.88, versus prior guidance of $1.65-$1.75 and the consensus of $1.80. Alexion Pharmaceuticals, Inc. sees FY2012 revenue of $1.110-$1.125 billion, versus prior guidance of $1.065-$1.085 billion and the consensus of $1.09 billion.
For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.
Alexion Pharmaceuticals, Inc. sees FY2012 EPS of $1.78-$1.88, versus prior guidance of $1.65-$1.75 and the consensus of $1.80. Alexion Pharmaceuticals, Inc. sees FY2012 revenue of $1.110-$1.125 billion, versus prior guidance of $1.065-$1.085 billion and the consensus of $1.09 billion.
For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Aptera Motors (SEV) Reports Q2 Loss of $0.20
- ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
